3 Medicare Cost Increases That Could Hurt Social Security Recipients in 2026

Medicare out-of-pocket costs rise in 2026 and will likely erode much of a 2.8% Social Security COLA (up from 2.5% in 2025). Key changes include the standard Part B premium rising to $202.90 from $185 (a $17.90 increase), the Part A inpatient deductible increasing to $1,736 from $1,676, coinsurance for hospital days 61–90 rising to $434 (from $419), and lifetime reserve day coinsurance to $868 (from $838). The increases compress disposable income for beneficiaries reliant on Social Security and could modestly reduce senior consumer spending, but they are unlikely to be market-moving on a macro scale.

Analysis

Market structure: Higher Medicare Part A/B cost-sharing is an income shock for retirees and should reallocate demand toward products that smooth out out-of-pocket risk. Winners: Medicare Advantage and supplemental insurers (UNH, HUM, CVS) and PBMs that can bundle predictable premiums; losers: discretionary retailers/restaurants skewed to older consumers and hospital operators exposed to deferred or uncompensated care (HCA). This shifts pricing power toward insurers that manage utilization and away from fee-for-service providers; expect MA plan pricing power and enrollment gains over 6–24 months.

Risk assessment: Tail risks include a regulatory response (Congress or CMS) capping Part B premium growth or re-pricing provider reimbursements, and political actions that could redistribute margins from private insurers to public payors. Immediate effect (days–weeks): investor repricing of hospital earnings; short term (3–12 months): enrollment flows into MA and Medigap; long term (2–5 years): structural margin improvement for efficient insurers. Hidden dependencies: employer retiree plans, Medicaid expansion, and state budget pressures that can amplify hospital bad-debt.

Trade implications: Position tactically long health-insurance exposure and short hosptials/elderly-discretionary exposure. Specifics: establish a 1.5% long in UNH and 1% long in HUM within 2–6 weeks, target +10–15% in 6–12 months, stop-loss 7–8%. Establish a 0.75% short in HCA (or hospital REIT HCN) to capture near-term utilization pressure. Options: buy a 6–9 month UNH call spread (buy ATM, sell +10–15% OTM) size 0.5% notional to skew risk/reward and reduce cost.

Contrarian angles: The market may underprice accelerated MA penetration—if Part B/coinsurance drag persists, MA enrollment could rise >3–5ppt over 2 years, favoring efficient vertically integrated players (UNH/OPTUM) more than traditional insurers. Conversely, short-term political backlash (premium caps or enhanced benefits) could temporarily compress insurer multiples — use any regulatory-driven pullbacks as buying opportunities rather than exit signals. Monitor CMS premium announcements and Medicare Trustees report (next 30–90 days) as primary catalysts.

Key Decisions for Investors

• Establish a 1.5% long position in UnitedHealth (UNH) within 2–6 weeks; target +10–15% upside over 6–12 months based on MA enrollment tailwinds and Optum margin leverage; set a stop-loss at -8%.
• Establish a 1.0% long position in Humana (HUM) as a complementary MA play; target +10% in 6–12 months; stop-loss -8%; consider trimming on a >15% run-up.
• Establish a 0.75% short position in HCA Healthcare (HCA) or a hospital-focused REIT (HCN) to capture near-term utilization and bad-debt pressure; cover after 6–12 months or if hospital same-store admissions exceed consensus by >3%.
• Buy a 6–9 month UNH call spread (buy ATM, sell 10–15% OTM) sized at 0.5% notional as a leveraged, capped-risk play; roll or take profits if UNH rallies >12% or if CMS policy proposals materially change.
• Reduce discretionary/consumer exposure skewed to older demographics by 2–4% (reallocate into HC insurers or staples); monitor CMS Part B premium release and Medicare Trustees report in the next 30–90 days—if premiums accelerate further, increase insurer longs by +0.5–1.0%.